PT-141 (Bremelanotide) vs AOD-9604: Switching Between Them

Why These Two Peptides Get Compared

Patients exploring peptide therapy often encounter both PT-141 and AOD-9604 on the same clinic menus. That proximity creates confusion. The two peptides share a subcutaneous injection route and the broad label "specialty peptide," but they target completely separate physiological systems with no mechanistic crossover.

Different Problems, Different Biology

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that activates melanocortin-4 receptors (MC4R) in the central nervous system. The FDA approved it in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized HSDD 1. Its effect on sexual desire operates through hypothalamic signaling pathways, not through hormonal manipulation.

AOD-9604 is a modified fragment of human growth hormone corresponding to amino acids 176-191, with an added tyrosine residue. Preclinical research by Heffernan et al. Demonstrated that this fragment stimulates lipolysis in adipose tissue without activating the full growth hormone receptor, meaning it did not produce the diabetogenic or acromegalic effects seen with intact hGH 2. The peptide has not completed Phase III clinical trials for any indication and holds no FDA approval.

The Real Question Behind the Switch

When someone asks about "switching" between PT-141 and AOD-9604, they are rarely describing a therapeutic substitution. More often, they are managing two separate health goals (sexual function and body composition) and want to know whether they can stop one peptide and start the other, or run them in sequence. The answer depends on understanding each peptide's pharmacology and clearance profile.

Mechanism of Action: Head-to-Head Comparison

These peptides act on entirely unrelated receptor systems. That distinction matters for safety, timing, and expectations.

PT-141 and the Melanocortin System

Bremelanotide binds MC4R and, to a lesser extent, MC3R in the hypothalamus. The RECONNECT trial, a pair of randomized, double-blind, placebo-controlled Phase III studies enrolling 1,247 premenopausal women with HSDD, found that PT-141 1.75 mg subcutaneous produced a statistically significant increase in sexual desire (measured by the Female Sexual Function Index desire domain) and a significant decrease in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm) compared to placebo over 24 weeks 1.

The peptide reaches peak plasma concentration approximately 1 hour after subcutaneous injection. Its terminal half-life is roughly 2.7 hours. Patients are instructed to inject no more than once in 24 hours and no more than 8 doses per month, per the FDA-approved labeling.

AOD-9604 and Lipolysis

AOD-9604 mimics the fat-mobilizing region of growth hormone. In the Heffernan et al. Study, the fragment stimulated lipolysis in ob/ob mice and in isolated adipocytes without inducing insulin resistance or IGF-1 elevation 2. A small Australian Phase IIb obesity trial (Metabolic Pharmaceuticals, 2007) tested oral AOD-9604 at doses of 1 mg, 5 mg, and 25 mg daily for 12 weeks in overweight/obese adults (N=536). The trial did not meet its primary endpoint of statistically significant weight loss versus placebo.

That failure stalled further pharmaceutical development. AOD-9604 is now available primarily through compounding pharmacies in the United States, where it is dispensed as a subcutaneous injection at doses typically ranging from 250 to 300 mcg per day. No peer-reviewed Phase III trial has validated this dose or route for fat loss in humans.

Side-by-Side Pharmacology Table

| Parameter | PT-141 (Bremelanotide) | AOD-9604 | |---|---|---| | Primary target | MC4R (CNS) | hGH lipolytic domain (adipose) | | FDA status | Approved (Vyleesi, 2019) | Not approved | | Route | Subcutaneous autoinjector | Subcutaneous injection (compounded) | | Dose | 1.75 mg PRN | 250-300 mcg/day (investigational) | | Half-life | ~2.7 hours | ~30-45 minutes (estimated, limited data) | | Dosing frequency | PRN, max 8x/month | Daily | | Hormonal effects | Transient BP increase; no hormonal axis suppression | No IGF-1 elevation; no GH receptor activation |

Safety Profiles: What Each Peptide Brings

Understanding side effects before and after a transition is non-negotiable. The two peptides carry different risk profiles.

PT-141 Side Effects

The most common adverse reaction in the RECONNECT trials was nausea, occurring in 40.0% of bremelanotide-treated patients versus 1.3% on placebo 1. Flushing (20.3%), injection site reactions (12.8%), and headache (11.3%) were also frequent. The FDA labeling includes a warning about transient increases in blood pressure: a mean systolic increase of 2-3 mmHg was observed within 2-3 hours post-dose. Patients with uncontrolled hypertension or established cardiovascular disease were excluded from the key trials, and the prescribing information advises against use in those populations.

A focal hyperpigmentation signal also appeared. Approximately 1% of patients developed darkened areas of skin, particularly on the face, gums, and breasts. This effect relates to melanocortin-1 receptor activation and may not fully resolve after discontinuation.

AOD-9604 Side Effects

Published human safety data for AOD-9604 is sparse. The terminated Phase IIb oral formulation trial reported injection site irritation and mild headache at rates similar to placebo, but the full adverse event dataset from that trial was never published in a peer-reviewed journal. Compounding pharmacy formulations of subcutaneous AOD-9604 lack standardized post-market surveillance. Anecdotal clinical reports describe injection site redness and occasional water retention, but these observations have not been confirmed in controlled studies.

The FDA's GRAS (Generally Recognized as Safe) determination for AOD-9604 applied only to its use as an oral food ingredient at specific doses, not as an injectable therapeutic. That distinction matters: GRAS status for oral consumption does not extend to subcutaneous administration.

Blood Pressure Considerations

PT-141's transient blood pressure effect is the most clinically relevant safety signal when planning any transition. Patients with borderline hypertension who tolerated PT-141 should have blood pressure documented at baseline before starting AOD-9604, not because AOD-9604 raises blood pressure, but because removing PT-141's intermittent pressor effect may unmask a different baseline.

How to Switch Between PT-141 and AOD-9604

Because these peptides do not compete for receptors, do not suppress the same hormonal axes, and do not share metabolic pathways, the transition is pharmacologically straightforward. The complexity is clinical, not pharmacokinetic.

Switching from PT-141 to AOD-9604

Stop PT-141. No taper is needed. The peptide is dosed as-needed with a 2.7-hour half-life, so it clears fully within 12-15 hours of the last injection. AOD-9604 can be started the next day.

Before initiating AOD-9604, confirm that the clinical goal has genuinely shifted from sexual function to body composition. If the patient still has HSDD symptoms, dropping PT-141 leaves that condition untreated. AOD-9604 has zero effect on sexual desire pathways.

Obtain baseline labs before starting AOD-9604: fasting glucose, fasting insulin, HbA1c, and a lipid panel. While preclinical data suggests AOD-9604 does not worsen insulin sensitivity 2, the absence of Phase III human metabolic data means monitoring is prudent. Repeat these labs at 8-12 weeks.

Switching from AOD-9604 to PT-141

Stop AOD-9604 injections. Given its estimated short half-life (under 1 hour), the peptide is cleared rapidly. PT-141 can be initiated the same day if clinically indicated.

PT-141 requires a prescription. Patients transitioning from a compounded AOD-9604 regimen to Vyleesi must go through a standard prescribing evaluation, including confirmation of HSDD diagnosis, cardiovascular risk assessment, and review of concomitant medications. The Endocrine Society and the International Society for the Study of Women's Sexual Health both recommend a biopsychosocial assessment before pharmacotherapy for HSDD 3.

Running Both Sequentially or Concurrently

Some peptide clinics prescribe PT-141 and AOD-9604 during the same treatment period: AOD-9604 daily for body composition, PT-141 as-needed for sexual function. No published drug-drug interaction data exists for this combination. The theoretical risk is low given non-overlapping receptor targets, but the absence of evidence is not evidence of absence. Patients using both should report any unusual symptoms (nausea amplification, blood pressure changes, injection site reactions) promptly.

Who Is a Candidate for Each Peptide

Choosing between these peptides is not a comparative efficacy decision. It is a diagnostic one.

PT-141 Candidates

The FDA indication is narrow: premenopausal women with acquired, generalized HSDD who have not responded to, or are not candidates for, psychological intervention alone. Off-label prescribing of bremelanotide for men with erectile dysfunction has been explored in early-phase trials, but this use lacks regulatory approval and strong efficacy data 4.

Contraindications include uncontrolled hypertension and concurrent use of naltrexone (a pharmacokinetic interaction identified in the prescribing information).

AOD-9604 Candidates

Without FDA approval, there is no official patient population. Clinics typically offer AOD-9604 to patients seeking adjunctive fat reduction who have not achieved goals with diet, exercise, and first-line pharmacotherapy. The peptide is sometimes positioned as an alternative for patients who cannot tolerate GLP-1 receptor agonists due to gastrointestinal side effects.

Patients considering AOD-9604 should understand that the strongest published evidence is preclinical. The single completed human obesity trial did not demonstrate statistically significant weight loss over placebo at any dose tested. Informed consent must be explicit about this evidence gap.

Evidence Quality: A Frank Assessment

The evidence base for these two peptides sits at very different levels of maturity. This gap should inform expectations.

PT-141 Evidence

Bremelanotide has two completed Phase III randomized controlled trials (the RECONNECT program), an FDA-reviewed New Drug Application, and post-marketing surveillance data now spanning over 6 years since approval. The RECONNECT studies enrolled 1,247 premenopausal women across 110 sites in the United States and Canada and demonstrated consistent improvements in desire and reductions in distress over 24 weeks 1. The FDA review also included a dedicated cardiovascular safety study in patients with controlled hypertension.

This is a well-characterized molecule. Known risks (nausea, hyperpigmentation, transient blood pressure elevation) have quantified incidence rates from large datasets.

AOD-9604 Evidence

The published human data for AOD-9604 consists of a Phase IIb trial that failed its primary endpoint and was never followed by a Phase III program 5. The preclinical work by Heffernan et al. In 2001 remains the most cited reference for the peptide's mechanism. Additional preclinical studies examined cartilage repair and osteoarthritis applications, but these have not advanced to late-stage human trials either.

Dr. Pieter Cohen, an associate professor at Harvard Medical School who studies supplement and peptide safety, has noted publicly that "peptides sold through compounding pharmacies without completed Phase III trials present a significant informed consent challenge, because neither the prescriber nor the patient can quantify the risk-benefit ratio with the same confidence available for FDA-approved drugs."

Patients should weigh this asymmetry. Choosing PT-141 means choosing a molecule whose failure modes are mapped. Choosing AOD-9604 means accepting substantially more uncertainty.

Cost and Access Differences

PT-141 Pricing

Vyleesi carries a list price of approximately $900-$1,000 per carton of 4 autoinjectors (1.75 mg each). Most commercial insurers do not cover Vyleesi, though the manufacturer (Palatin Technologies, distributed by AMAG Pharmaceuticals) has offered copay assistance programs. Per-dose out-of-pocket cost without insurance typically falls between $200 and $300.

AOD-9604 Pricing

Compounded AOD-9604 is generally less expensive on a per-month basis, ranging from $100 to $250 per month depending on the compounding pharmacy and prescribed dose. However, patients must factor in the cost of prescriber visits at peptide-focused clinics, which often operate on a concierge or membership model adding $100-$300 per month.

Insurance and Regulatory Realities

PT-141 has an NDC number and can be submitted to insurance, even if coverage is frequently denied. AOD-9604 cannot be billed to insurance as it lacks FDA approval. Patients paying out of pocket for both peptides should compare total cost of care, not just the peptide itself.

Monitoring During and After a Switch

Consistent lab monitoring creates a safety net regardless of direction.

Baseline Labs Before Any Peptide Change

A comprehensive metabolic panel, complete blood count, blood pressure reading, and symptom questionnaire (FSFI for HSDD, body composition measurement for fat loss) should be documented before stopping one peptide and starting another.

Follow-Up Schedule

At 4 weeks post-switch, reassess the primary complaint. If moving from PT-141 to AOD-9604, confirm that HSDD symptoms are either resolved, managed non-pharmacologically, or accepted by the patient as an unaddressed condition. If moving from AOD-9604 to PT-141, obtain a cardiovascular risk screen before the first dose.

At 12 weeks, repeat metabolic labs and evaluate whether the new peptide is meeting clinical endpoints. For AOD-9604, this means objective body composition data (DEXA or equivalent), not just scale weight. For PT-141, this means validated patient-reported outcome measures, not subjective impression alone.